Evidence map›Paper›PMID 33556616›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.

Tawanda Gumbo, Carleton M Sherman, Devyani Deshpande, Jan-Willem Alffenaar, Shashikant Srivastava

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Eradication of Drug-TolerantMicroorganisms · 2023
    Review
  4. T405, a New Penem, ExhibitsAntimicrobial agents and chemotherapy · 2022
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Tawanda GumboCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA; Praedicare Laboratories and Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, TX, USA; Department of Medicine, University of Cape Town, Observatory, South Africa.
Carleton M ShermanCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA; Praedicare Laboratories and Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, TX, USA.
Devyani DeshpandeCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Jan-Willem AlffenaarThe University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, Australia; Westmead Hospital, Sydney, Australia; Marie Bashir Institute of Infectious Diseases, The University of Sydney, Sydney, Australia.
Shashikant SrivastavaCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA; Department of Pulmonary Immunology, University of Texas Health Science Centre, Tyler, TX, USA. Electronic address: Shashi.kant@uthct.edu.
Baylor University Medical Center · USTaronga Conservation Society Australia · AU

Funding

PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TBR01HD099756 · NICHD · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2019 to 2023
$1.6M
NICHD NIH HHS R01 HD099756
6 · The paper itself

Abstract

backgroundFaropenem (F), an orally bioavailable β-lactam, kills Mycobacterium tuberculosis (Mtb) without the help of a β-lactamase inhibitor. This study explored the sterilizing effect of adding F once or twice daily to a linezolid (L) plus pyrazinamide (Z) backbone regimen.

methodsIn vitro studies were performed using the hollow fiber model of tuberculosis (HFS-TB) to compare the kill rates of: 1) ZL two-drug combination; 2) F administered once daily plus ZL (F

resultsMtb in the non-treated HFS-TB grew at a rate of 0.018 ± 0.007 log

conclusionDue to the slow kill rate compared to standard therapy, FZL regimens are unlikely to shorten therapy duration. Efficacy of these regimens against drug-resistant tuberculosis needs to be determined.

Indexed as

Antitubercular Agentsbeta-LactamsDrug Therapy, CombinationDuration of TherapyHumansLinezolidMycobacterium tuberculosisPyrazinamideTreatment FailureTuberculosisAntitubercular Agentsbeta-LactamsfropenemLinezolidPyrazinamideSterilizing activityTherapy durationTuberculosisβ-lactam

Identifiers

PMID33556616
PMCPMC8168785
OpenAlexW3126207882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.